All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Phase II study assesses the use of rituximab and bendamustine in frail, elderly DLBCL patients

May 29, 2018

Bookmark this article

On 10 May 2018, a study was published in Haematologica assessing the use of rituximab and bendamustine in combination as front line therapy for frail elderly patients with diffuse large B-cell lymphoma (DLBCL). The paper was published by Sergio Storti, Universita Cattolica Sacro Cuore Campbasso, Italy, and colleagues from the Fondazione Italiana Linfomi (Italian Lymphoma Foundation).

The phase II study (NCT01990144) evaluated the efficacy and safety of the combination of bendamustine and rituximab in patients with previously untreated DLBCL. Patients were defined as ‘frail’ in-line with the Comprehensive Geriatric Assessment (CGA). The study addressed an unmet need in this patient population for the treatment of frail elderly patients who are unable to be treated with the standard R-CHOP therapy.

Study Overview

  • The open-label, non-randomized study assessed N = 45 patients (median age = 81 years; range, 71–89) from Italian centers
  • Patients received 4-6 courses of bendamustine (90 mg/m2, Days 1-2) and rituximab (375 mg/m2, Day 1) administered every 28 days
  • Primary endpoints included Complete Remission Rate (CR) and safety. Secondary endpoints included; overall response rate (ORR), progression-free survival (PFS) and overall survival (OS)

Key Findings

  • Median follow-up = 33 months (range, 1–52)
  • CR: 53% (95% CI, 38–68%)
    • Partial remission (n = 4)
  • ORR: 62% (95% CI, 47–76%)
  • 2-year PFS: 38% (95% CI, 24–51%)
    • Median PFS: 10 months (95% CI, 7–25)
  • 2-year OS: 51% (95% CI, 35–65%)
    • Median OS: 30 months (95% CI, 10–not reached)
  • Most common adverse event grade ≥3 was neutropenia 37.8%
    • 24 patients died during the study treatment and follow-up due to; lymphoma disease progression (58%) and unrelated causes

The authors concluded that they found the combination of bendamustine and rituximab to be a good treatment option showing “promising activity” for elderly frail patients with DLBCL. They noted that a larger sample size would be needed to further assess the PFS and OS in this treatment population.

  1. Storti S. Et al. Rituximab plus bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin’s lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi. Haematologica. 2018 May 10. pii: haematol.2017.186569. doi: 10.3324/haematol.2017.186569. [Epub ahead of print]

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

Which treatment do you select for patients with follicular lymphoma after multiple relapses?
0 votes - 6 days left ...


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox